Insulin Validations: in-vitro testing and scaling

rBIO has advanced its bio-production capabilities by selecting an optimized expression vector for commercial applications, successfully scaling fermentation processes from 0.2L to 2L, and evaluating and validating expression conditions. The team, in partnership with Aurigene Pharmaceutical Services, also developed purification and analytical methods and confirmed in-vitro biochemical activity of the expressed insulin.